Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease
2016 NCCN Annual Conference (1)
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.
Judith Paice, PhD, RN, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses strategies for safe opioid prescribing: making a comprehensive assessment, stratifying risk, using universal precautions, and educating practitioners on safe storage and disposal.
Daniel T. Chang, MD, of the Stanford Cancer Institute, discusses the role of radiation therapy in the treatment of hepatocellular carcinoma.
Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
Kenneth Anderson, MD, of Dana-Farber Cancer Institute, discusses how the many advances in the treatment of multiple myeloma affect current and future clinical practice.